µå·¯±×ÀÎÆ÷¸ÞÀÎ
 

»óº´Äڵ忡 µû¸¥ »óº´¸íÀ» È®ÀÎ ÇϽǼö ÀÖ½À´Ï´Ù.  
»óº´ÄÚµå ÇÑ±Û»óº´¸í ¿µ¹®»óº´¸í
Y481 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºñ°æ±¸¸¶ÃëÁ¦ Parenteral anesthetics causing adverse effects in therapeutic use
Y481 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ŸÀÌ¿À¹ÙºñÃò·¹ÀÌÆ® Thiobarbiturate causing adverse effects in therapeutic use
Y482 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Àü½Å¸¶ÃëÁ¦ Other and unspecified general anesthetics causing adverse effects in therapeutic use
Y483 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¹¼Ò¸¶ÃëÁ¦ Local anesthetic causing adverse effects in therapeutic use
Y484 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ¸¶ÃëÁ¦ Anesthetics, unspecified causing adverse effects in therapeutic use
Y485 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °¢Á¾ Ä¡·á¿ë°¡½º Therapeutic gases causing adverse effects in therapeutic use
Y49 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº Á¤½ÅÀÛ¿ë¾à¹° Psychotropic drugs, NEC causing adverse effects in therapeutic use
Y490 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Æ®¸®»çÀÌŬ¸¯ ¹× Åׯ®¶ó»çÀÌŬ¸¯ Ç׿ì¿ïÁ¦ Tricyclic and tetracyclic antidepressants causing adverse effects in therapeutic use
Y491 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸ð³ë¾Æ¹Î-¿Á½Ãµ¥À̽º ¾ïÁ¦¼º Ç׿ì¿ïÁ¦ Monoamine-oxidase-inhibitor antidepressants causing adverse effects in therapeutic use
Y492 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Ç׿ì¿ïÁ¦ Other and unspecified antidepressants causing adverse effects in therapeutic use
Y493 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Æä³ëµð¾ÆÁø Ç×Á¤½Åº´ ¾àÁ¦ ¹× ½Å°æÀÌ¿ÏÁ¦ Phenothiazine antipsychotics and neuroleptics causing adverse effects in therapeutic use
Y494 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºÎƼ·ÎÆä³í ¹× Áö¿Á»êƾ ½Å°æÀÌ¿ÏÁ¦ Butyrophenone and thioxanthene neuroleptics causing adverse effects in therapeutic use
Y495 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç×Á¤½Åº´¾àÁ¦ ¹× ½Å°æÀÌ¿ÏÁ¦ Other antipsychotics and neuroleptics causing adverse effects in therapeutic use
Y496 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ȯ°¢Á¦ Psychodysleptics [hallucinogens] causing adverse effects in therapeutic use
Y497 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ³²¿ëÀÇ ÀáÀ缺ÀÌ ÀÖ´Â Á¤½ÅÈïºÐÁ¦ Psycostimulants with abuse potential causing adverse effects in therapeutic use
Y498 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ Á¤½ÅÀÛ¿ë¾à¹° Other psychotropic drugs, NEC causing adverse effects in therapeutic use
Y499 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ Á¤½ÅÀÛ¿ë¾à¹° Psychotropic drug, unspecified causing adverse effects in therapeutic use
Y50 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ÁßÃ߽Űæ°èÅë ÈïºÐÁ¦ Central nervous system stimulants, NEC causing adverse effects in therapeutic use
Y500 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °¢¼ºÁ¦ Analeptics causing adverse effects in therapeutic use
Y501 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾ÆÆí¼ö¿ëü±æÇ×Á¦ Opioid reactor antagonists causing adverse effects in therapeutic use
1911  1912  [1913] 1914  1915  1916  1917  1918  1919  1920